Bonk (NASDAQ:BNKK) Issues Earnings Results

Bonk (NASDAQ:BNKK – Get Free Report) issued its earnings results on Monday. The company reported ($0.46) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.88 million during the quarter. Bonk had a negative net margin of 952.21% and a negative return on equity of 137.47%.

Bonk Price Performance

Shares of BNKK stock traded down $0.05 on Tuesday, reaching $0.76. 28,622 shares of the company were exchanged, compared to its average volume of 570,140. The company has a 50-day moving average of $1.30 and a 200-day moving average of $1.95. The company has a market cap of $6.03 million, a price-to-earnings ratio of -0.20 and a beta of 1.86. Bonk has a one year low of $0.71 and a one year high of $8.90.

Hedge Funds Weigh In On Bonk

An institutional investor recently bought a new position in Bonk stock. BlackRock Inc. acquired a new stake in shares of Bonk, Inc. (NASDAQ:BNKK – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 33,188 shares of the company’s stock, valued at approximately $50,000. BlackRock Inc. owned about 0.41% of Bonk at the end of the most recent reporting period. 12.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bonk in a report on Thursday, October 22nd. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Read Our Latest Stock Analysis on BNKK

Bonk Company Profile

(Get Free Report)

Safety Shot, Inc., a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners.

Read More

Earnings History for Bonk (NASDAQ:BNKK)

Receive News & Ratings for Bonk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bonk and related companies with MarketBeat.com's FREE daily email newsletter.